clinical trial · NCT06698887
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
Bristol-Myers Squibb·—·recruiting·n = 15
Multiple MyelomaIdecabtagene vicleucel
brief summary
The purpose of this study is to monitor the long-term safety of participants who received idecabtagene vicleucel treatment as part of the KarMMa-9 (CA089-1043) Phase 3 clinical trial.
started
Sep 11, 2024
primary completion
Mar 27, 2031
completion
Mar 27, 2031
last updated
Dec 13, 2024
official title
Long-Term Safety Follow-Up Surveillance for Phase 3 Trial (KarMMA-9/CA089-1043) to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol